Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to shrink stomach tumors before surgery

NCT ID NCT06829797

Recruiting now Disease control Sponsor: Shandong Provincial Hospital Source: ClinicalTrials.gov ↗

First seen May 01, 2026 · Last updated May 14, 2026 · Updated 3 times

Summary

This study tests whether adding a new immunotherapy combination (iparomlimab and tuvonralimab) to standard chemotherapy can better shrink locally advanced stomach or gastroesophageal junction cancer before surgery. About 96 adults with stage T3N+ or T4a cancer that hasn't spread will be randomly assigned to get either the immunotherapy plus chemo or chemo alone. The main goal is to see if more patients have no cancer cells left in the removed tissue after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shandong Provincial Hospital

    RECRUITING

    Jinan, Shandong, 250021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA